dc.contributor.author | Hawley, C. | |
dc.contributor.author | Turner, M. | |
dc.contributor.author | Latif, M.A. | |
dc.contributor.author | Curtis, V. | |
dc.contributor.author | Saleem, P.T. | |
dc.contributor.author | Wilton, K. | |
dc.date.accessioned | 2010-02-25T09:53:59Z | |
dc.date.available | 2010-02-25T09:53:59Z | |
dc.date.issued | 2010 | |
dc.identifier.citation | Hawley , C , Turner , M , Latif , M A , Curtis , V , Saleem , P T & Wilton , K 2010 , ' Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone : reasons for switching and safety ' , Human Psychopharmacology: Clinical and Experimental , vol. 25 , no. 1 , pp. 37-46 . https://doi.org/10.1002/hup.1085 | |
dc.identifier.issn | 0885-6222 | |
dc.identifier.other | dspace: 2299/4311 | |
dc.identifier.uri | http://hdl.handle.net/2299/4311 | |
dc.description | ‘The definitive version is available at www3.interscience.wiley.com '. Copyright John Wiley & Sons, Ltd. [Full text of this article is not available in the UHRA] | |
dc.description.abstract | Objective: An international, non-randomised study evaluated efficacy and safety of risperidone long-acting injectable (RLAI) compared to previous treatment. To investigate generisability of the European data set to the UK subset safety and switching data are reported here. Methods: Patients with schizophrenia or other psychotic disorder, symptomatically stable on antipsychotic medication, received intramuscular injections of RLAI 25 mg (to a maximum of 50 mg) every 2 weeks for 6 months. Results: Of 182 UK patients enrolled, 79% had schizophrenia, 21% other psychotic disorders. Insufficient efficacy (43%), side effects (45%), and non-compliance (25%) were the most common reasons for switching. Sixty-nine per cent of patients completed the trial; 8% discontinued due to adverse events (AEs). Most frequent treatment-emergent AEs were headache (8.2%), relapse (7.7%) and insomnia (7.1%); 8 (4.4%) patients reported injection-related AEs. There were significant improvements in extrapyramidal symptom rating scale total and subscale (particularly Parkinsonism) scores, regardless of previous medication (total cohort, p0.0001). There was a small but significant increase in body weight at endpoint (1.2kg, p = 0.0023). One patient suffered a myocardial infarction and died (not treatment-related). There were no substantial differences between the full data set and the UK sub-population Conclusion: Switch to RLAI was well-tolerated in stable patients over 6 months. The European data set is generalisable to the UK patient population. | en |
dc.language.iso | eng | |
dc.relation.ispartof | Human Psychopharmacology: Clinical and Experimental | |
dc.title | Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone : reasons for switching and safety | en |
dc.contributor.institution | Centre for Postgraduate Medicine | |
dc.description.status | Peer reviewed | |
rioxxterms.versionofrecord | 10.1002/hup.1085 | |
rioxxterms.type | Journal Article/Review | |
herts.preservation.rarelyaccessed | true | |